DOI=10.5795/jjscc.32.1
Yoshida M., Kiyozuka Y., Noda T., Imai S., Ichijo M.
Establishment and characterization of human cell line derived from mucinous cystadenocarcinoma of ovary.
Nihon Rinsho Saibo Gakkai Zasshi 32:1-8(1993)

PubMed=8718548
Murakami F.
Cytotoxic action of monoclonal antibodies OC125 and SH-9 on ovarian cancer cell lines.
Nihon Sanka Fujinka Gakkai Zasshi 48:125-132(1996)

DOI=10.1063/1.1291135
Kiyozuka Y., Takemoto K., Yamamoto A., Guttmann P., Tsubura A., Kihara H.
X-ray microimaging of cisplatin distribution in ovarian cancer cells.
AIP Conf. Proc. 507:153-153(2000)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=19154404; DOI=10.1111/j.1349-7006.2008.01065.x
Sato S., Itamochi H., Kigawa J., Oishi T., Shimada M., Sato S., Naniwa J., Uegaki K., Nonaka M., Terakawa N.
Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy.
Cancer Sci. 100:546-551(2009)

PubMed=22246397; DOI=10.3892/or.2012.1626
Sato N., Saga Y., Mizukami H., Wang D., Fujiwara H., Takei Y., Machida S., Ozawa K., Suzuki M.
Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations.
Oncol. Rep. 27:1336-1340(2012)